Prognostic Factor Analysis of Intraocular Pressure with Neovascular Glaucoma

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/joph/volume-2016/1205895/figures/1205895.fig.006a.svgz" name="1205895.fig.006a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Additional PRP</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/joph/volume-2016/1205895/figures/1205895.fig.006b.svgz" name="1205895.fig.006b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>PPV</td></tr><tr class="fig-image" id="c"><td><object data="https://static.hindawi.com/articles/joph/volume-2016/1205895/figures/1205895.fig.006c.svgz" name="1205895.fig.006c" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(c) </b>LEC</td></tr></table>

<div>Post-treatment IOP with or without anti-VEGF combination therapy. All treatments with or without anti-VEGF combination therapy had a significant effect on IOP. No significant differences in post-treatment IOP were observed between patients treated with or without anti-VEGF combination therapy.</div>

Journal of Ophthalmology

fig6

Figure 6

Figure 6: Prognostic Factor Analysis of Intraocular Pressure with Neovascular Glaucoma 